Patents by Inventor Norman Edward Sharpless

Norman Edward Sharpless has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HEMATOPOIETIC PROTECTION AGAINST CHEMOTHERAPEUTIC COMPOUNDS USING SELECTIVE CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS
    Publication number: 20150111896
    Abstract: Methods for reducing or preventing the effects of cytotoxic compounds in healthy cells are provided. The methods relate to the use of selective cyclin-dependent kinase (CDK) 4/6 inhibitors to induce transient quiescence in CDK4/6 dependent cells, such as hematopoietic stem cells and/or hematopoietic progenitor cells. Also described is a method of selecting compounds for reducing or preventing the effects of cytotoxic agents compounds in healthy cells.
    Type: Application
    Filed: September 24, 2014
    Publication date: April 23, 2015
    Inventors: Norman Edward Sharpless, Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Matthew R. Ramsey
  • LKB1/STK11 DELETION IN MELANOMA AND RELATED METHODS
    Publication number: 20140378469
    Abstract: LKB1 mutation status and/or expression, YES expression and phosphorylation level; and/or CD24 expression are employed to predict melanoma prognosis and response to therapeutics. Inhibitors (including targeted inhibitors) of SRC family kinases (especially YES) are employed to treat melanoma.
    Type: Application
    Filed: February 6, 2013
    Publication date: December 25, 2014
    Inventors: Norman Edward Sharpless, Wenjin Liu, James Bear, Kimberly Monahan, Kwok-Kin Wong
  • PROTECTION OF RENAL TISSUES FROM ISCHEMIA THROUGH INHIBITION OF THE PROLIFERATIVE KINASES CDK4 AND CDK6
    Publication number: 20130303543
    Abstract: The presently disclosed subject matter relates to methods and compositions for protecting cells and or tissues from damage due to ischemia. In particular, the presently disclosed subject matter relates to the protective action of cyclin dependent kinase 4/6 (CDK4/6) lithibitors administered to subjects that have been exposed to, or that are at risk of, ischemia.
    Type: Application
    Filed: November 17, 2011
    Publication date: November 14, 2013
    Applicant: The University of North Carolina at Chapel Hill
    Inventors: Derek Paul DiRocco, Norman Edward Sharpless, Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Benjamin Duane Humphreys, Kwok-Kin Wong